SCAI President Srihari S. Naidu, MD, a veteran interventional cardiologist, made a major impact on the group—and cardiology as a whole—over the last 12 months.
A majority of deaths from Friedreich's ataxia are associated with heart complications. A new treatment years in the making could provide some much-needed relief.
Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.
“Rather than condemning all added sugars, future dietary guidelines might consider the differential effects of sugar based on its source and form," one researcher said.
Mario Gaudino, MD, PhD, spoke to Cardiovascular Business about minimally invasive procedures, the growing interest in clinical trials and other key trends in the world of cardiac surgery.
ACT-EARLY is testing the hypothesis that treating asymptomatic carriers of a pathogenic TTR variant with the drug acoramidis could delay amyloidosis from developing.
The Philips Azurion interventional imaging system was recently updated with new ultralow dose technology that is said to reduce X-ray exposure by up to 50% during coronary procedures.
